PA8499601A1 - Procedimientos para preparar inhibidores de 5-lipoxigenasa que tienen sistemas anuladores heterociclicos variados - Google Patents

Procedimientos para preparar inhibidores de 5-lipoxigenasa que tienen sistemas anuladores heterociclicos variados

Info

Publication number
PA8499601A1
PA8499601A1 PA20008499601A PA8499601A PA8499601A1 PA 8499601 A1 PA8499601 A1 PA 8499601A1 PA 20008499601 A PA20008499601 A PA 20008499601A PA 8499601 A PA8499601 A PA 8499601A PA 8499601 A1 PA8499601 A1 PA 8499601A1
Authority
PA
Panama
Prior art keywords
naoh
solvent
formula
koh
reaction mixture
Prior art date
Application number
PA20008499601A
Other languages
English (en)
Inventor
Timothy Norris
Megan Elizabeth Hnatow
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8499601A1 publication Critical patent/PA8499601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE DESCRIBE UN PROCEDIMIENTO PARA PREPARAR UN COMPUESTO DE FORMULA (1.3.0): EN LA CUAL (ICLUYE DIBUJOS) QUE COMPRENDE: ESTABLECER UNA MEZCLA DE REACCIÓN COMPUESTA POR (INCLUYE DIBUJOS) EN UN DISOLVENTE APRÓTICO; EN PRESENCIA DE NAOH Ó DE KOH; OPCIONALMENTE EN PRESENCIA DE UN CATALIZADOR DE TRANSFERENCIA DE FASE, EN ESPECIAL UNA SAL DE AMONIO CUATERNARI O UNA SAL DE FOSFONIO; SEGUIDO POR CALENTAR DICHA MEZCLA DE REACCIÓN BAJO UNA ATMOSFERA DE NITRÓGENO; EN UNA REALIZACIÓN PREFERIDA, EL DISOLVENTE APRÓTICO ES DMSO, LA LA BASE FUERTE EN FORMA SÓLIDA ES NAOH EN FORMA DE POLVO O DE GRANULOS, Y EL CATALIZADOR DE TRANSFERENCIA DE FASE CLORO DE TETRA-N-BUTILAMONIO (TBAC), EN EL CUAL EL MATERIAL DE PARTIDA DE FORMULA (2.0.0) ES PREPARADO DE LA MANERA SIGUIENTE: SE HACEN REACCIONR JUNTOS EN UN DISOLVENTE COMPUESTO POR UN ALCOHOL ALIFÁTICO DE CADENA LINEAL O RAMIFICADA; EN PRESENCIA DE UNA BASE FUERTE COMPUESTA POR NAOH Ó KOH; EN PRESENCIA DE METAL DE TRANSICIÓN QUE COMPRENDE UN COMPLEJO DE METAL PALADIO; Y AÚN ADEMÁS EN PRESENCIA DE UN LIGANDO AUXILIAR QUE COMPRENDE UN COMPUESTO AROMÁTICO BIDENTADO, QUIRAL, AUXIALMENTE DISIMÉTRICO, DE FORMULA (5.5.0) Ó (5.5.1).
PA20008499601A 1999-08-31 2000-08-10 Procedimientos para preparar inhibidores de 5-lipoxigenasa que tienen sistemas anuladores heterociclicos variados PA8499601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
PA8499601A1 true PA8499601A1 (es) 2002-02-21

Family

ID=22539510

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008499601A PA8499601A1 (es) 1999-08-31 2000-08-10 Procedimientos para preparar inhibidores de 5-lipoxigenasa que tienen sistemas anuladores heterociclicos variados

Country Status (33)

Country Link
EP (1) EP1081144A3 (es)
JP (1) JP2001106686A (es)
KR (1) KR20010050274A (es)
CN (1) CN1286251A (es)
AP (1) AP2000001909A0 (es)
AR (1) AR022650A1 (es)
AU (1) AU5370200A (es)
BG (1) BG104730A (es)
BR (1) BR0003888A (es)
CA (1) CA2316748A1 (es)
CO (1) CO5180623A1 (es)
CZ (1) CZ20003159A3 (es)
EA (1) EA200000803A3 (es)
EE (1) EE200000513A (es)
GT (1) GT200000144A (es)
HR (1) HRP20000565A2 (es)
HU (1) HUP0003437A3 (es)
ID (1) ID27128A (es)
IL (1) IL138089A0 (es)
IS (1) IS5604A (es)
MA (1) MA26750A1 (es)
NO (1) NO20004312L (es)
NZ (1) NZ506633A (es)
OA (1) OA11451A (es)
PA (1) PA8499601A1 (es)
PE (1) PE20010523A1 (es)
PL (1) PL342280A1 (es)
SG (1) SG87145A1 (es)
SK (1) SK12862000A3 (es)
SV (1) SV2002000160A (es)
TN (1) TNSN00176A1 (es)
TR (1) TR200002530A2 (es)
UY (1) UY26315A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112837A1 (ja) * 2003-05-23 2004-12-29 Hisamitsu Pharmaceutical Co., Inc. 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン-1α生成抑制剤
EP1834953A1 (en) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
CN103980312B (zh) * 2014-05-27 2016-09-07 广州大学 一种n杂环双膦配体及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze

Also Published As

Publication number Publication date
HU0003437D0 (en) 2000-08-30
IL138089A0 (en) 2001-10-31
EA200000803A3 (ru) 2001-06-25
CZ20003159A3 (cs) 2001-12-12
EP1081144A3 (en) 2001-04-11
CO5180623A1 (es) 2002-07-30
TR200002530A2 (tr) 2001-04-20
MA26750A1 (fr) 2004-12-20
EP1081144A2 (en) 2001-03-07
TNSN00176A1 (fr) 2005-11-10
SG87145A1 (en) 2002-03-19
OA11451A (en) 2003-12-08
NO20004312L (no) 2001-03-01
KR20010050274A (ko) 2001-06-15
GT200000144A (es) 2002-02-20
BR0003888A (pt) 2001-12-11
NZ506633A (en) 2001-12-21
PL342280A1 (en) 2001-03-12
AR022650A1 (es) 2002-09-04
ID27128A (id) 2001-03-01
CN1286251A (zh) 2001-03-07
PE20010523A1 (es) 2001-04-28
SV2002000160A (es) 2002-01-23
EA200000803A2 (ru) 2001-04-23
JP2001106686A (ja) 2001-04-17
NO20004312D0 (no) 2000-08-30
HUP0003437A2 (hu) 2001-06-28
AP2000001909A0 (en) 2000-09-30
AU5370200A (en) 2001-03-08
UY26315A1 (es) 2001-04-30
EE200000513A (et) 2001-04-16
IS5604A (is) 2001-03-01
SK12862000A3 (sk) 2002-02-05
HUP0003437A3 (en) 2002-08-28
CA2316748A1 (en) 2001-02-28
BG104730A (en) 2001-09-28
HRP20000565A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
WO2003016923A3 (en) Hydroxypyridonate and hydroxypyrimidinone chelating agents
TW200628667A (en) Chemical composition and process
WO2006136279A3 (en) Gas-forming agent for cement composition
EP2039693A3 (en) Novel synthesis of irbesartan
PA8499601A1 (es) Procedimientos para preparar inhibidores de 5-lipoxigenasa que tienen sistemas anuladores heterociclicos variados
WO2001029156A3 (en) Thiadizole dimer additives and lubricating compositions containing the same
AR030505A1 (es) Proceso para la preparacion de fenilacetronitrilos sustituidos
DE60107398D1 (de) Steuerbares entriegelungsmechanismus, insbesondere für luftfahrttechnik
AU9093901A (en) Creatine ester pronutrient compounds and formulations
WO2001094317A3 (en) Method for synthesis of substituted azole libraries
DE60101784D1 (de) Synthese von wasserlöslischem 9-dihydroplacitaxel derivate aus 9-dihydro-13-acetylbacchatin iii
ES2117791T3 (es) Beta-aminovinilcetonas, un procedimiento de preparacion y su utilizacion en la preparacion de beta-dicetonas.
AU2001260419A1 (en) Use of n,n'-dibenzyl ethylene diamine n,n'-diacetic acid derivatives as anti-pollution agent
ES2186057T3 (es) Procedimiento para la obtencion de piridilmetiliso-tiocianatos.
WO2002022569A8 (de) Verfahren zur herstellung chiraler verbindungen
MY120732A (en) Process for the preparation of a metal salt of clavulanic acid
DK1188681T3 (da) Beskyttelsesemballage til en cylindrisk genstand, forsynet med et fastgörelsesmiddel
Higgins Hungry for large parts? Try a composite sandwich.
WO2002017920A3 (en) Use of methylphenidate compounds to enhance memory
AR022649A1 (es) Procedimiento para la obtencion de inhibidores de 5-lipooxigenasa con distintos sistemas de anillos heterociclos.
WO2003051795A3 (de) Harzgebundene isonitrile
ZA200204593B (en) Sustained-release formulation of a cyclooxygenase-2 inhibitor.
WO2001000138A3 (en) Use of hydroxydiphenyl ether class of chemicals, as exemplified by triclosan, as an antimalarial and identification of fatty acid synthesis as its target
Kaiser Tech program: Half-full or half-empty?
Mandel A day in 2020.